Given the potential biological link between insulin resistance and tumor progression, it is worth investigating the feasibility of adding insulin sensitizers (such as metformin) or adjusting the intensity of adjuvant chemotherapy for high-risk patients on top of standard treatment. Here, INS is linked to neoplasm.